Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from all of us cohort.

European journal of cancer (Oxford, England : 1990) - 1 Dec 2024

Wang Yanfei, Xiong Chenxi, Yu Weifeng, Zhou Minghao, Shugg Tyler, Hsu Fang-Chi, Eadon Michael T, Su Jing, Song Qianqian

Abstract excerpt

INTRODUCTION: Immune checkpoint inhibitors (ICIs) enhance the immune system's ability to target and destroy cancer cells, but can also trigger immune-related adverse events (irAEs), such as acute kidney injury (ICI-AKI), complicating patient management. Limited knowledge of genetic predispositions to ICI-AKI highlights the need for genomic studies to improve therapeutic strategies. OBJECTIVE: To identify genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Kidney Injury
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Immune Checkpoint Inhibitors

Share to Neoplasms

Share to Polymorphism, Single Nucleotide

Share to Risk Factors

Share to United States

Source

Identifiers

PMID: 39536432
DOI: 10.1016/j.ejca.2024.115114

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from all of us cohort.PMID 39536432Read ↗

PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from All of Us cohortSemantic proximity Read ↗

Exploring the gut microbiome and immunological landscape in kidney cancer: a Mendelian randomization analysisSemantic proximity Read ↗

Germline genetic variation and predicting immune checkpoint inhibitor induced toxicitySemantic proximity Read ↗

Association between programmed death protein 1-related single-nucleotide polymorphisms and immune-related adverse events induced by programmed death protein 1 inhibitors-a pilot study.Semantic proximity Read ↗

Influence of interleukin-18 polymorphisms on kidney transplantation outcomes: a meta-analysisSemantic proximity Read ↗

Germline variants associated with immunotherapy-related adverse eventsSemantic proximity Read ↗

Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: A retrospective studySemantic proximity Read ↗

Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitorsSemantic proximity Read ↗

Beyond GWAS-Could Genetic Differentiation within the Allograft Rejection Pathway Shape Natural Immunity to COVID-19?Semantic proximity Read ↗

Phenotypic insights into genetic risk factors for immune-related adverse events in cancer immunotherapy.Semantic proximity Read ↗

Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitorsSemantic proximity Read ↗

Tumor-Promoting vs. Protective Immune Phenotypes in Stage III Colorectal Cancer: A Mendelian Randomization Study on Chemotherapy OutcomesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.